Skip to main content

Cellgenemedix

Cancer testing

Cancer Genomics Research

CellGeneMedix develops molecular assays that help match cancer patients to the right therapy. Our work focuses on fast, low-cost detection of treatment-guiding mutations, and on sequencing workflows for broader genomic profiling.

KRAS and BRAF mutation detection in colorectal cancer

KRAS and BRAF V600E status determines whether a colorectal cancer patient is a candidate for anti-EGFR antibody therapy. Our founder, Dr. Jung Joo Moon, designed a five-color multiplex real-time PCR assay using ARMS (amplification refractory mutation system) primers and probes.

  • Reports wild-type KRAS and wild-type or mutant (V600E / V600K) BRAF status
  • About four hours of running time in a single run
  • Runs on widely used real-time PCR instruments (CFX96 and ABI 7500)
Poster Presentation, American Society for Clinical Pathology (ASCP) 2024 Annual Meeting. Published in the American Journal of Clinical Pathology (2024; Vol. 162, Suppl. 1).

Breast cancer sequencing libraries: Nanopore and Illumina

We are developing sequencing library workflows for breast cancer gene panels on two complementary platforms:

Illumina short-readThe established standard for accurate variant calling.
Oxford Nanopore long-readReads through long and complex regions and can give same-day results.

Comparing the two on the same samples is intended to show where long-read sequencing adds information to standard short-read testing.

Research use only. Not for diagnostic use. Not cleared or approved by the U.S. FDA.